Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Elizabeth Iannotti Buchbinder, M.D.


This page shows the publications co-authored by Elizabeth Buchbinder and David McDermott.
Connection Strength

  1. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49.
    View in: PubMed
    Score: 0.824
  2. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52.
    View in: PubMed
    Score: 0.697
  3. Cytotoxic T-lymphocyte antigen-4 blockade in melanoma. Clin Ther. 2015 Apr 01; 37(4):755-63.
    View in: PubMed
    Score: 0.626
  4. Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am. 2014 Jun; 28(3):571-83.
    View in: PubMed
    Score: 0.587
  5. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15.
    View in: PubMed
    Score: 0.161
  6. Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. Melanoma Res. 2019 02; 29(1):70-76.
    View in: PubMed
    Score: 0.051
  7. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J Immunother. 2017 01; 40(1):31-35.
    View in: PubMed
    Score: 0.044
  8. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.